Trubion Pharma (TRBN) Reports Q2 Loss of 28c, Beats by 6c; Guides FY10 Sales
Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN) reports Q2 loss of $0.28, 6 cents better than the analyst estimate of ($0.34). Revenue for the quarter was $5.7 million, which compares to the estimate of $6.36 million.
Sees FY10 sales guidance to $19-$24 million. The Street is looking for sales of $24.8 million.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
Sees FY10 sales guidance to $19-$24 million. The Street is looking for sales of $24.8 million.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
You May Also Be Interested In
- UPDATE: Bristow Group (BRS) Reports Better-Than-Expected Q4 Results; Offers FY13 Outlook
- Tiffany & Co. (TIF) Misses Q1 EPS Views; Lowers FY12 EPS, Revs Growth Outlook
- Jiayuan.com (DATE) Reports In-Line Q1 EPS of 5c; Guides Q2 Revs
Create E-mail Alert Related Categories
Earnings, GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
